bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Significant Decrease in Short Interest

bioAffinity Technologies, Inc. (NASDAQ:BIAF) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 226,200 shares, a decrease of 16.7% from the October 31st total of 271,400 shares. Based on an average trading volume of 123,400 shares, the days-to-cover ratio is currently 1.8 days. Currently, 2.4% of the company’s shares are sold short.

bioAffinity Technologies Trading Up 3.8 %

Shares of NASDAQ BIAF traded up $0.05 during mid-day trading on Friday, reaching $1.22. The company had a trading volume of 22,697 shares, compared to its average volume of 138,038. The stock has a market cap of $18.94 million, a price-to-earnings ratio of -1.48 and a beta of 3.10. bioAffinity Technologies has a 52 week low of $1.03 and a 52 week high of $3.62. The business’s 50-day moving average is $1.56 and its 200-day moving average is $1.89. The company has a current ratio of 1.02, a quick ratio of 1.01 and a debt-to-equity ratio of 0.18.

Institutional Investors Weigh In On bioAffinity Technologies

An institutional investor recently bought a new position in bioAffinity Technologies stock. Ground Swell Capital LLC purchased a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned 0.20% of bioAffinity Technologies as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 1.64% of the company’s stock.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.